PURPOSE: Spectral domain optical coherence tomography (SD-OCT) allows cross-sectional visualization of retinal structures in vivo. Here, the authors report the efficacy of a commercially available SD-OCT device to study mouse models of retinal degeneration. METHODS: C57BL/6 and BALB/c wild-type mice and three different mouse models of hereditary retinal degeneration (Rho(-/-), rd1, RPE65(-/-)) were investigated using confocal scanning laser ophthalmoscopy (cSLO) for en face visualization and SD-OCT for cross-sectional imaging of retinal structures. Histology was performed to correlate structural findings in SD-OCT with light microscopic data. RESULTS: In C57BL/6 and BALB/c mice, cSLO and SD-OCT imaging provided structural details of frequently used control animals (central retinal thickness, CRT(C57BL/6) = 237 +/- 2 microm and CRT(BALB/c) = 211 +/- 10 microm). RPE65(-/-) mice at 11 months of age showed a significant reduction of retinal thickness (CRT(RPE65) = 193 +/- 2 microm) with thinning of the outer nuclear layer. Rho(-/-) mice at P28 demonstrated degenerative changes mainly in the outer retinal layers (CRT(Rho) = 193 +/- 2 microm). Examining rd1 animals before and after the onset of retinal degeneration allowed monitoring of disease progression (CRT(rd1 P11) = 246 +/- 4 microm, CRT(rd1 P28) = 143 +/- 4 microm). Correlation of CRT assessed by histology and SD-OCT was high (r(2) = 0.897). CONCLUSIONS: The authors demonstrated cross-sectional visualization of retinal structures in wild-type mice and mouse models for retinal degeneration in vivo using a commercially available SD-OCT device. This method will help to reduce numbers of animals needed per study by allowing longitudinal study designs and will facilitate characterization of disease dynamics and evaluation of putative therapeutic effects after experimental interventions.
PURPOSE: Spectral domain optical coherence tomography (SD-OCT) allows cross-sectional visualization of retinal structures in vivo. Here, the authors report the efficacy of a commercially available SD-OCT device to study mouse models of retinal degeneration. METHODS: C57BL/6 and BALB/c wild-type mice and three different mouse models of hereditary retinal degeneration (Rho(-/-), rd1, RPE65(-/-)) were investigated using confocal scanning laser ophthalmoscopy (cSLO) for en face visualization and SD-OCT for cross-sectional imaging of retinal structures. Histology was performed to correlate structural findings in SD-OCT with light microscopic data. RESULTS: In C57BL/6 and BALB/c mice, cSLO and SD-OCT imaging provided structural details of frequently used control animals (central retinal thickness, CRT(C57BL/6) = 237 +/- 2 microm and CRT(BALB/c) = 211 +/- 10 microm). RPE65(-/-) mice at 11 months of age showed a significant reduction of retinal thickness (CRT(RPE65) = 193 +/- 2 microm) with thinning of the outer nuclear layer. Rho(-/-) mice at P28 demonstrated degenerative changes mainly in the outer retinal layers (CRT(Rho) = 193 +/- 2 microm). Examining rd1 animals before and after the onset of retinal degeneration allowed monitoring of disease progression (CRT(rd1P11) = 246 +/- 4 microm, CRT(rd1P28) = 143 +/- 4 microm). Correlation of CRT assessed by histology and SD-OCT was high (r(2) = 0.897). CONCLUSIONS: The authors demonstrated cross-sectional visualization of retinal structures in wild-type mice and mouse models for retinal degeneration in vivo using a commercially available SD-OCT device. This method will help to reduce numbers of animals needed per study by allowing longitudinal study designs and will facilitate characterization of disease dynamics and evaluation of putative therapeutic effects after experimental interventions.
Authors: Mathias W Seeliger; Susanne C Beck; Naira Pereyra-Muñoz; Susann Dangel; Jen-Yue Tsai; Ulrich F O Luhmann; Serge A van de Pavert; Jan Wijnholds; Marijana Samardzija; Andreas Wenzel; Eberhart Zrenner; Kristina Narfström; Edda Fahl; Naoyuki Tanimoto; Niyazi Acar; Felix Tonagel Journal: Vision Res Date: 2005-09-26 Impact factor: 1.886
Authors: F Marlhens; C Bareil; J M Griffoin; E Zrenner; P Amalric; C Eliaou; S Y Liu; E Harris; T M Redmond; B Arnaud; M Claustres; C P Hamel Journal: Nat Genet Date: 1997-10 Impact factor: 38.330
Authors: Baerbel Rohrer; Heather R Lohr; Peter Humphries; T Michael Redmond; Mathias W Seeliger; Rosalie K Crouch Journal: Invest Ophthalmol Vis Sci Date: 2005-10 Impact factor: 4.799
Authors: M Frasson; S Picaud; T Léveillard; M Simonutti; S Mohand-Said; H Dreyfus; D Hicks; J Sabel Journal: Invest Ophthalmol Vis Sci Date: 1999-10 Impact factor: 4.799
Authors: Stefanie M Hauck; Per A R Ekström; Poonam Ahuja-Jensen; Sabine Suppmann; Francois Paquet-Durand; Theo van Veen; Marius Ueffing Journal: Mol Cell Proteomics Date: 2005-10-26 Impact factor: 5.911
Authors: Seifollah Azadi; Francois Paquet-Durand; Patrik Medstrand; Theo van Veen; Per A R Ekström Journal: Mol Cell Neurosci Date: 2006-02-28 Impact factor: 4.314
Authors: M M Humphries; D Rancourt; G J Farrar; P Kenna; M Hazel; R A Bush; P A Sieving; D M Sheils; N McNally; P Creighton; A Erven; A Boros; K Gulya; M R Capecchi; P Humphries Journal: Nat Genet Date: 1997-02 Impact factor: 38.330
Authors: T M Redmond; S Yu; E Lee; D Bok; D Hamasaki; N Chen; P Goletz; J X Ma; R K Crouch; K Pfeifer Journal: Nat Genet Date: 1998-12 Impact factor: 38.330
Authors: Haoyu Mao; Marina S Gorbatyuk; Brian Rossmiller; William W Hauswirth; Alfred S Lewin Journal: Hum Gene Ther Date: 2012-03-28 Impact factor: 5.695
Authors: Eric J Knott; Kristopher G Sheets; Yongdong Zhou; William C Gordon; Nicolas G Bazan Journal: Exp Eye Res Date: 2010-10-28 Impact factor: 3.467